Tempest Therapeutics (NASDAQ:TPST) Earns Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report released on Friday, Benzinga reports. Piper Sandler currently has a $8.00 price target on the stock.

A number of other research firms have also recently weighed in on TPST. Scotiabank initiated coverage on shares of Tempest Therapeutics in a report on Thursday, March 14th. They set a sector outperform rating and a $13.00 price objective on the stock. William Blair reaffirmed an outperform rating on shares of Tempest Therapeutics in a report on Wednesday, March 20th. Finally, HC Wainwright reaffirmed a buy rating and issued a $47.00 target price on shares of Tempest Therapeutics in a report on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Tempest Therapeutics presently has a consensus rating of Buy and an average price target of $20.75.

Tempest Therapeutics Stock Up 1.0 %

TPST stock opened at $2.03 on Friday. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. Tempest Therapeutics has a twelve month low of $0.17 and a twelve month high of $9.77. The company’s 50 day moving average is $3.24 and its two-hundred day moving average is $3.69. The stock has a market cap of $45.10 million, a P/E ratio of -1.18 and a beta of -1.78.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. Research analysts expect that Tempest Therapeutics will post -1.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC acquired a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics comprises about 0.0% of MayTech Global Investments LLC’s holdings, making the stock its 29th largest position. MayTech Global Investments LLC owned approximately 0.05% of Tempest Therapeutics as of its most recent SEC filing. 22.52% of the stock is currently owned by institutional investors and hedge funds.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.